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Dr R. Duane Davis (Durham, NC). First a disclosure. We are
being supported by Vitrolife. They funded the US trial.
Marcelo, congratulations on an excellent presentation. You and
your colleagues at the University of Toronto have again demon-
strated the safety and efficacy of using EVLP to enable the trans-
plantation of lungs that would previously not have been used by
your group. In the United States, lung disease is the fourth most
common cause of death; it accounts for approximately 125,000
deaths per year. We perform approximately 2000 lung transplants
per year. So you could say there is an approximate 122,000 short-
fall in the number of transplants that potentially could be done. Ob-
viously that is a bit of an overestimation; not of all those would be
appropriate candidates. But using this technology, we may start to
be able to apply LTx more effectively for societal needs. As you
have mentioned, only approximately 17% of the lungs in the
United States from consented donors actually yield lungs for1206 The Journal of Thoracic and Cardiovascular Surtransplant. So my questions are going to be primarily focused on
the overall impact that EVLP may have on LTx.
In your group’s experience, 86% of the lungs treated with EVLP
were subsequently transplanted, and they now account for approx-
imately 20% of the overall transplants you perform at Toronto.
However, this yield seems to be substantially different than what
we are seeing in the US trial. Currently, approximately 54% of
lungs (1 of 2) treated with EVLP are being transplanted. This
is fairly consistent with data from the United Kingdom and other
countries.
What do you think are the differences? Are you using lungs that
we would have conventionally used or lungs that may actually fit
better with the operating room schedule, that is, operations are oc-
curring at 2 AM, and this allows you to do it during the daytime?
Dr Cypel. That is an interesting point. To be relatively direct
about that, none of these perfusions were performed because we
would be able to perform transplantations at a less disruptive
time. It is an interesting concept and totally feasible, because we
have shown that we can safely keep these organs 12 hours in the
system without any added injury. But that was not the case in
this specific population.
The main difference in our higher use rates compared with the
other groups that more recently started with EVLP is based on the
experience that our group has with the procedure. We have exten-
sive laboratory research, performing EVLP in more than 100 large
animals and in rejected human lungs before starting a clinical trial,
and this is different than the current scenario at other centers. That
is part of the answer. I also think it is related to the donor selection.
More recently, we have pushed the limits further; consequently, we
have used fewer lungs after EVLP. I think it depends on the donor
selection criteria.
Dr Davis. Although the overall cohort of patients receiving
EVLP lungs had essentially identical outcomes to those of patients
receiving conventional lungs, the patients receiving EVLP lungs
from the DCDs had an approximate 20% 6-month mortality. Al-
though this is not statistically significant, it does raise some con-
cern, particularly when we are starting to think about going into
the uncontrolled DCD or the Maastricht categories 1 and 2, where
we could substantially increase the donor pool.
Does this raise concerns, and have you looked at things such as
warm ischemic time in these DCDs to try to get an early signal?
Although there are few events, it would be nice to know if there
are things that we should avoid in the DCD population.
Dr Cypel. We have looked at the causes of death in these 4 re-
cipients who received DCD lungs after EVLP and died in the first 6
months. Two of those were patients who had a diagnosis of cepa-
cia-positive cystic fibrosis and ultimately died of cepacia sepsis af-
ter being discharged from the hospital. The third patient had
a massive retroperitoneal hematoma after being anticoagulated
for atrial fibrillation, and the fourth patient died of gram-negative
sepsis, so the deaths were not really related to the quality of the
graft. We are happy with our low incidence of PGD after transplan-
tation using DCD lungs.
In regard to your question of the interval of time from with-
drawal of life-support therapies to cardiac arrest, there was really
no difference, but as you mentioned, I think the numbers are small.
The Australian experience has shown that perhaps there is a signal
there, but I think when we put all the data together from thegery c November 2012
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be able to discriminate that better.
Dr Davis. My final question is basically to look in the crystal
ball. We are currently performing 2000 lung transplants. You say
that approximately 20% of the lungs you use are being treated
nowwith EVLP, but you actually have been static at approximately
100 lung transplants per year. So even though you have this new
technology, it has not seemed to increase the volume of transplants
you are performing. The goal in the United States is to achieve
40% to 50% use or to double or triple the number of transplants.
With EVLP as it is now, where do you think it is going to actu-
ally drive the number of transplants in the United States without
doing things such as gene therapy or other resuscitation therapies
on the lungs?The Journal of Thoracic and CarDr Cypel. For the first part of the question, our numbers have
been stable at 100 in the last 2 years; the organ donation rates in
our organ procurement organization have decreased in the last 2
years, and all solid-organ transplant numbers have decreased in
our institution, and we are able to keep our number stable. I think
it did make a contribution on that end.
The major contribution of EVLP will not be for the large num-
ber of transplant centers with high use rates (eg, Duke or Toronto)
and that already use 40% of the organs. Their margin of increase is
not that large, but if we look at the majority of lung transplant cen-
ters that use less than 10% of the offered lungs, that is where we
can make a major impact, increasing the number of organs
available.
Dr Davis. Again, congratulations.diovascular Surgery c Volume 144, Number 5 1207
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